Summary
Eli Lilly has given hospitals in the 340B drug discount program until Monday, June 9, 2026, to comply with data sharing requirements — or lose access to 340B pricing on Lilly’s medicines. The company is requiring providers to submit claims data for all Lilly drugs dispensed in 340B, to verify that providers are not claiming duplicate discounts across 340B and Medicaid simultaneously. Hospitals contend the mandate violates the law and urge HRSA to intervene. Consequently, the dispute carries implications that extend well beyond Lilly — and well beyond this deadline.
Access Impact
The 340B program is a structural feature of US market access for specialty drugs. Lilly’s top-selling medicines — including Mounjaro and Zepbound (tirzepatide) — are dispensed in significant volumes through 340B-eligible facilities that serve low-income and vulnerable patients. Specifically, if hospitals lose 340B access, effective pricing for those facilities increases immediately — directly affecting Budget Impact and Affordability, two core domains of MARA’s market access framework. Moreover, this change occurs without any formal price adjustment, making it invisible to standard pricing benchmarks.
Budget Impact
340B discounts are embedded in hospital formulary decisions and procurement models. When manufacturers impose compliance conditions — or withdraw discounts for non-compliance — the effective net price changes without appearing as a formal price increase. This creates an access risk that does not surface in list pricing data or even in reported net price trends. For drugs with significant 340B dispensing volume, the effective payer landscape can shift materially based on a single policy enforcement action. Portfolio holders who have modelled revenue on assumed 340B penetration are therefore carrying a risk that standard pricing analysis does not capture.
Affordability and Patient Access
The 340B program was specifically designed to help safety-net hospitals subsidize care for the most vulnerable populations. If manufacturers restrict program access through compliance enforcement, the affordability impact reaches patients — not just payers. For specialty medicines, this means reduced dispensing in exactly the facilities that serve the highest-need populations. From a market access perspective, access breadth — which directly influences real-world uptake and commercial projections — narrows without any change to formal coverage status.
Precedent Risk
Lilly’s ultimatum is not isolated. Novo Nordisk announced a similar data sharing requirement immediately after Lilly’s January announcement. If HRSA does not intervene, multiple large manufacturers are expected to adopt comparable policies. Furthermore, any enforcement precedent set here will influence how discount programs — including Medicaid rebates — are structured and audited going forward. The risk is not limited to 340B. It points toward a broader shift in how access-linked discounts are managed across the US market.
Risk Signal
Access structures approved at launch are not permanent. The 340B dispute illustrates a core principle: market access is a moving agreement between manufacturers, payers, and intermediaries — subject to unilateral revision by any party with leverage. For drugs with high 340B volume, revenue projections that assume current discount access are exposed. The relevant question for portfolio holders is straightforward: if 340B access for this asset is restructured or restricted, what is the impact on commercial revenue and payer coverage?
#MarketAccess #HTA #MARArating #DrugPricing
Explore market access risk assessment: https://mararating.com/market-access-pharma/
Explore MARA ratings list: https://mararating.com/mara-ratings-list